MEKanistic Therapeutics
Website
Leadership
Danny Cunagin, Chief Executive Officer
Neal Meyer, Chief Financial Officer
Judy Sebolt-Leopold, Chief Strategy Officer
Chris Whitehead, Chief Operating Officer
Adam Becker, Development Officer
Founded
2022
Industry
Biotechnology
Led by cancer research pioneers, MEKanistic Therapeutics is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window by inhibiting compensatory resistance pathways at the same time, avoiding inherent toxicity challenges of multi-compound treatments.